SINGAPORE--(BUSINESS WIRE)--Invida Group, the leading specialty biopharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has completed a joint venture agreement with the Indonesian pharmaceutical manufacturer MUGI. The acquisition of MUGI will allow Invida to leverage its full suite of capabilities throughout Indonesia and open up the Indonesian market for Invida’s partners, as well as allowing Invida to offer a range of partnering options unique on this scale in Indonesia.
